Almost every addiction-medicine vignette and prescribing station eventually asks you to choose between the two maintenance agonists. Understanding methadone vs buprenorphine maintenance as a pharmacology-driven decision — not a trivia list — is what lets you justify induction doses, monitoring intervals and discharge plans under pressure.
This article works through the receptor biology, the induction rules that differ between them, a feature-by-feature comparison table, the QTc and overdose evidence, and which patient fits which drug. If you are revising for MRCPsych or an ABPN/USMLE-style opioid block, the comparison and the two callouts are the parts worth committing to memory.
Methadone vs buprenorphine: the pharmacology in one paragraph
Methadone is a full mu-opioid receptor agonist with additional weak NMDA-antagonist activity. Given repeatedly, it accumulates because its half-life is long and variable (roughly 15–60 hours, commonly around 24 hours), reaching steady state over about 4–10 days. Full receptor occupancy produces tolerance to euphoria and sedation faster than to constipation and QT effects — hence the classic profile of a stabilised patient who is not intoxicated but is still genuinely prescribed a strong opioid.
Buprenorphine is a high-affinity partial mu agonist (with kappa-opioid antagonist activity) with a sublingual half-life of roughly 24–42 hours. Its partial efficacy produces a plateau — the ceiling effect — above which further receptor occupancy adds little respiratory depression. It also out-competes full agonists at the receptor because of its high affinity, which is the double-edged pharmacology behind both its safe switching profile and its potential to precipitate withdrawal if given while a full agonist still occupies the receptor.
Induction: where the two protocols diverge
Induction is the highest-risk moment in either pathway and the single most examined difference.
- Buprenorphine induction: start only once moderate withdrawal is established — conventionally a clinical opioid withdrawal scale score in the moderate range (around 8–12 for short-acting opioids), because residual full-agonist occupancy triggers precipitated withdrawal. An initial 2–4 mg sublingual dose is typical, with a further 2–4 mg after 1–2 hours of observation; total day-one dosing commonly lands at 4–8 mg, and most patients are stable on 8–24 mg daily by the end of the first week, with 16 mg the frequently cited standard dose.
- Methadone induction: no precipitated-withdrawal trap, but a respiratory-depression and accumulation trap instead. Typical starting doses are 10–30 mg daily — reduced to the lower end where tolerance is uncertain, abstention has been long, or sedatives are in the picture — with the first dose given under observation. Doses are then adjusted in 5–10 mg steps only after a review interval of at least several days, because the true steady-state effect of day one does not declare itself until roughly a week later.
Whichever you choose, the principle is identical: titrate to retention and function, not to a fixed number. NICE NG115 frames both drugs as options within a wider package of psychosocial care, and dose escalation beyond a textbook figure is a sign to review the whole plan rather than to stop at the plan.
Exam trap: ceiling effect vs QTc prolongation
The two highest-yield safety facts travel as a pair. Buprenorphine's partial agonism gives it a ceiling on respiratory depression, so it has a wider margin in overdose and in patients who also use alcohol or benzodiazepines — but it is not harmless, because deaths still occur with co-ingestants. Methadone, as a full agonist with no ceiling, carries dose-related overdose risk concentrated in the first weeks of treatment and after any treatment interruption, and it prolongs the QTc interval in a dose-dependent fashion.
Side-by-side: methadone vs buprenorphine maintenance
| Feature | Methadone | Buprenorphine (sublingual) |
|---|---|---|
| Receptor action | Full mu agonist; weak NMDA antagonism | Partial mu agonist; kappa antagonism |
| Approx. half-life | 15–60 h; steady state 4–10 days | 24–42 h |
| Typical induction | 10–30 mg day 1, observe, then 5–10 mg steps | 2–4 mg once withdrawal moderate; 4–8 mg day 1 |
| Usual maintenance | 60–100 mg daily (some need 80–120 mg) | 8–24 mg daily (16 mg commonly standard) |
| Cardiac monitoring | ECG in at-risk patients and during titration, especially above 100 mg/day | No meaningful QT signal; ECG not routinely required |
| Overdose profile | No ceiling; risk front-loaded in first weeks | Respiratory-depression ceiling; safer in overdose |
| Cochrane retention evidence | Modestly better retention, especially at higher doses | Effective, slightly lower retention in head-to-head reviews |
| Practical flexibility | Usually daily supervised dosing initially; take-home opens with stability | Same dosing framework; fewer visits once stable, fewer QT concerns with polypharmacy |
All figures are approximations drawn from NICE NG115, the BNF/SmPC entries and published trial ranges; local protocols and formularies differ, so check the current guidance you are working under.
QTc, cardiac risk and methadone monitoring
Methadone blocks the hERG potassium channel, producing dose-dependent QT prolongation, and Torsades de Pointes has been reported, though serious arrhythmia remains rare at conventional doses. Risk multiplies when you stack other QT-prolonging drugs — many antipsychotics, antidepressants, macrolides and antiemetics — or when potassium, magnesium and calcium are deranged, which is common in actively using patients.
In practice this translates to three moves. First, obtain baseline ECG and correct electrolytes in anyone with cardiac history, syncope, family history of sudden death, bradycardia, or concurrent QT-prolonging medication. Second, repeat ECG during titration, particularly as the daily dose climbs above 100 mg. Third, act on the accepted threshold for drug-induced QT prolongation: a QTc above 500 ms, or an increase of more than 60 ms from baseline, warrants review of the dose and the interacting drug list. Buprenorphine sidesteps most of this: at clinical doses it does not meaningfully prolong the QTc, which is one reason it is attractive for patients on antipsychotics or antidepressants.
Overdose safety, mortality and the evidence base
Both agonists dramatically reduce all-cause mortality compared with no maintenance treatment — the consistent finding across the Cochrane reviews of methadone and buprenorphine maintenance, and the reason withdrawal-only approaches are hard to defend. Between the two, Mattick et al.'s Cochrane review (2014) found methadone modestly superior for retaining people in treatment, particularly at higher doses, while buprenorphine showed a more favourable side-effect and overdose profile. Large observational cohorts have additionally reported lower all-cause mortality with buprenorphine than with methadone in routine care, although confounding by indication means this should be read as association rather than proof of superiority.
The distinction that survives into exams is mechanical: the ceiling belongs to buprenorphine. A patient who takes extra doses, or who layers benzodiazepines on top, hits a plateau with buprenorphine that does not exist with methadone. Conversely, methadone's risk is time-dependent — the hazard of a missed dose followed by an unsupervised restart, or of a "clock-up" after incarceration or hospital discharge, is a well-recognised killer.
So which patient gets which?
Lean buprenorphine when…
- There is ongoing sedative use, or significant polypharmacy with other QT-prolonging drugs.
- Overdose risk is a specific concern — unstable housing, recent release, prior non-fatal overdose.
- The patient is pregnant: buprenorphine monotherapy is widely used in pregnancy, with randomised data (the MOTHER trial) showing comparable retention to methadone and less severe neonatal opioid withdrawal syndrome.
- The patient needs flexibility early and values fewer supervised visits.
Lean methadone when…
- Retention has been the failure point with previous treatments — higher full-agonist doses often secure engagement.
- The patient has a long, high-dose full-agonist history where partial agonism was not tolerated or did not suppress cravings.
- Cardiac and electrolyte risk is low and the QT issue can be monitored rather than avoided.
- Long-acting depot buprenorphine is unavailable in the service, and adherence to daily sublingual dosing would be unreliable.
NICE NG115 is deliberately agnostic about which is "better": the right choice is the one the patient will actually take, within a service that can monitor safely. That sentence is close to a model answer in itself.
Frequently asked questions
Which is better for opioid maintenance: methadone vs buprenorphine?
Methadone is a full mu-opioid agonist with no ceiling, given orally, requiring a 4–10 day accumulation period, typical maintenance of 60–100 mg daily and QTc-aware monitoring. Buprenorphine is a partial mu agonist with a high receptor affinity and a respiratory-depression ceiling, given sublingually, usually titrated to 8–24 mg daily. Methadone tends to hold slightly more patients in treatment; buprenorphine is safer in overdose and with sedative co-use.
Why must buprenorphine wait for withdrawal before the first dose?
Because buprenorphine's receptor affinity is higher than that of most full agonists, giving it while heroin, fentanyl or methadone still occupies mu receptors displaces the full agonist and precipitates an abrupt, severe withdrawal. Waiting until moderate withdrawal is present — conventionally a score around 8–12 on a clinical opioid withdrawal scale — means endogenous and exogenous agonist activity has fallen far enough that buprenorphine's partial activity relieves rather than worsens symptoms.
Does methadone prolong the QTc and how often should you do an ECG?
Yes, methadone prolongs the QTc in a dose-dependent manner via hERG channel block. Obtain a baseline ECG (with electrolytes) in anyone with cardiac risk factors or taking other QT-prolonging drugs, repeat during dose titration — particularly as the dose exceeds 100 mg daily — and review the regimen if the QTc exceeds 500 ms or rises more than 60 ms from baseline. Buprenorphine does not produce clinically meaningful QT prolongation.
Which is safer in an overdose: methadone or buprenorphine?
Buprenorphine, because its partial agonism produces a plateau in respiratory depression and its long duration protects against re-intoxication once stabilised. Methadone has no such ceiling, and overdose risk is highest in the first weeks of treatment, after dose escalation, and after any interruption in dosing. The protection is relative, not absolute: co-ingestion of alcohol, benzodiazepines or other sedatives still causes deaths on buprenorphine.
Key takeaways
- Full agonist (methadone) vs partial agonist (buprenorphine) explains every downstream difference — ceiling, QTc, induction timing.
- Buprenorphine needs moderate withdrawal before the first dose to avoid precipitated withdrawal; methadone needs an observing window and a slow titration because of accumulation.
- Usual ranges: methadone 60–100 mg/day with ECG vigilance above 100 mg; buprenorphine 8–24 mg/day with no routine ECG.
- Both cut mortality versus no treatment; buprenorphine has the safer overdose profile, methadone the modestly better retention.
- Match the drug to the patient's risk pattern — sedative use and overdose vulnerability favour buprenorphine, retention failure and high prior tolerance favour methadone.
Opioid maintenance sits inside a much larger evidence base you are expected to command on exam day, and the MRCPsych addiction syllabus rewards exactly this kind of mechanism-first reasoning — practise it with a timed mock exam before you sit the real thing.
Cover image: “Methadone vs Buprenorphine (cover)” by Preppsy Editorial Team (Original artwork) via Preppsy.
